← Back to Patent Explorer
US5403750A Expired / Lapsed US ⏱️ 0.0 years remaining

Biocompatible, low protein adsorption affinity matrix

Assignee: EMD Millipore Corp
•
Filing: 1991-04-08
•
Granted: 1995-04-04
•
Expires: 2011-04-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Affinity matrices useful for the chromatography and immobilization of biological materials and the method of preparing and using the same are disclosed. The affinity supports are based on hydrated polyurethane polymers which have been activated to provide a means for covalently attaching a variety of bioaffinity agents. The hydrated polymer matrices are characterized by their biocompatibility and resistance to nonspecific protein adsorption. Preferably, the prepolymers used to prepare the hydrated polymers are isocyanate-capped oxyethylene-based diols or polyols, at least 75% of said diols and polyols having a molecular weight of 7000 to about 30,000.

Inventors

  • 👤 James A. Braatz
  • 👤 Aaron H. Heifetz

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 19:58
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/28; A61L27/34; A61L33/00; A61L33/06; A61L33/068; B; B01; B01D; B01D15/00; B01D15/08; B01D15/26; B01D15/38; B01D15/3804; B01D15/3809; B01J; B01J20/00; B01J20/02; B01J20/10; B01J20/103; B01J20/20; B01J20/22; B01J20/26; B01J20/262; B01J20/28; B01J20/28002; B01J20/28004; B01J20/28014; B01J20/28016; B01J20/28054; B01J20/28078; B01J20/281; B01J20/282; B01J20/285; B01J20/286; B01J20/30; B01J20/32; B01J20/3202; B01J20/3204; B01J20/3214; B01J20/3225; B01J20/3227; B01J20/3231; B01J20/3242; B01J20/3268; B01J20/3272; C; C08; C08G; C08G18/00; C08G18/06; C08G18/08; C08G18/10; C08G18/28; C08G18/2805; C08G18/2815; C08G18/283; C08G18/40; C08G18/48; C08G18/4825; C08G18/4829; C08G18/4833; C08G18/4837; C08G18/485; C08G18/70; C08G18/72; C08G18/74; C08G18/75; C08G18/751; C08G18/752; C08G18/753; C08G18/755; C12; C12N; C12N5/00; C12N5/0068; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/543; G01N33/54313; G01N33/54393; G02; G02B; G02B1/00; G02B1/04; G02B1/041; G02B1/043; B01J2220/00; B01J2220/50; B01J2220/54; B01J2220/56; B01J2220/58; C08G2210/00; C12N2533/00; C12N2533/30; Y; Y10; Y10S; Y10S528/00; Y10S528/904; Y10T; Y10T428/00; Y10T428/31504; Y10T428/31551; Y10T428/31569; Y10T428/31573; Y10T428/3158; Y10T428/31591; Y10T428/31598; Y10T428/31601; Y10T436/00; Y10T436/18; Y10T436/182; Y10T436/20; Y10T436/200833; Y10T436/201666; Y10T436/203332

Claims Analysis

Total Claims: 27
Claim 1
Independent Claim 213 words
An affinity matrix for chromatography and immobilization of biologically active materials comprising a support having a polyurethane coating thereon of said polymer thereon, wherein said polyurethane polymer is derived from prepolymer units of oxyethylene based alcohols having essentially all of the hydroxyl groups capped with polyisocyanate groups and having at least 15% of said polyisocyanate groups reacted with a modifying compound having a first NCO reactive group and a second functional group having a substantially less NCO reactive group, and wherein said polyurethane polymer has been activated by converting said second functional groups to an active functional group capable of covalently attaching a bioaffinity agent, said matrix being characterized by a biocompatible surface which resists nonspecific protein adsorption, wherein the modifying compound is selected from the group consisting of ethanolamine; aminoethyl hydrogensulfate; taurine; 4-aminosulfonyl-1-hydroxy-2-napththoic acid; glucosamine; 5-(aminosulfonyl) N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide; sulfamylphenyl-D-glucosylamine; 4-carboxybenzene-sulfonamide; sulfanilamide; cyclic-adenosine monophosphate; 2-aminoethyl phosphonic acid; tyrosine; tyramine; dibutylamine; L- or DL-cysteine; L- or DL-cysteine ethyl ester; L- or DL-cystine dimethyl ester; L- or DL-Cystine; L- or DL-cysteinesulfonic acid; L- or DL-cysteic acid; cystamine; 2-mercaptoethanol; ethanethiol; glutathione; 3-amino-1,2-propanediol; 3-amino-1-propane sulfonic acid; 3-aminophenyl boronic acid; 2-amino-2-deoxy-D-galactose; 1-amino-1-deoxy-D-galactose; p-aminophenyl-alpha-D-glucose; p-aminophenyl-1-thio-beta-D-galactose; penicillamine; peptides with sulfhydryl groups; peptides with free amino groups; animal hormones; polysaccharides; lipids; nucleic acids; amino sugars; amino acids; amine surfactants; diamines and polyamines.
Claim 2
Dependent Claim 213 words
An affinity matrix for chromatography and immobilization of biologically active materials comprising a support having a polyurethane coating thereon of said polymer thereon, wherein said polyurethane polymer is derived from prepolymer units of oxyethylene based alcohols having essentially all of the hydroxyl groups capped with polyisocyanate groups and having at least 15% of said polyisocyanate groups reacted with a modifying compound having a first NCO reactive group and a second functional group having a substantially less NCO reactive group, and wherein said polyurethane polymer has been activated by converting said second functional groups to an active functional group capable of covalently attaching a bioaffinity agent, said matrix being characterized by a biocompatible surface which resists nonspecific protein adsorption, wherein the modifying compound is selected from the group consisting of ethanolamine; aminoethyl hydrogensulfate; taurine; 4-aminosulfonyl-1-hydroxy-2-napththoic acid; glucosamine; 5-(aminosulfonyl) N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide; sulfamylphenyl-D-glucosylamine; 4-carboxybenzene-sulfonamide; sulfanilamide; cyclic-adenosine monophosphate; 2-aminoethyl phosphonic acid; tyrosine; tyramine; dibutylamine; L- or DL-cysteine; L- or DL-cysteine ethyl ester; L- or DL-cystine dimethyl ester; L- or DL-Cystine; L- or DL-cysteinesulfonic acid; L- or DL-cysteic acid; cystamine; 2-mercaptoethanol; ethanethiol; glutathione; 3-amino-1,2-propanediol; 3-amino-1-propane sulfonic acid; 3-aminophenyl boronic acid; 2-amino-2-deoxy-D-galactose; 1-amino-1-deoxy-D-galactose; p-aminophenyl-alpha-D-glucose; p-aminophenyl-1-thio-beta-D-galactose; penicillamine; peptides with sulfhydryl groups; peptides with free amino groups; animal hormones; polysaccharides; lipids; nucleic acids; amino sugars; amino acids; amine surfactants; diamines and polyamines.
Claim 3
Dependent Claim 30 words
The matrix of claim 1 in which substantially all of said prepolymer units are oxyethylene-based diols or polyols having an average number molecular weight of about 7000 to about 30,000.
Claim 4
Dependent Claim 31 words
The matrix of claim 1 in which at least 75% of said prepolymer units are oxyethylene-based diols and polyols having an average number molecular weight of about 7000 to about 30,000.
Claim 5
Dependent Claim 19 words
The matrix of claim 2 in which said diols or polyols are capped with an aliphatic or cycloaliphatic polyisocyanate.
Claim 6
Dependent Claim 16 words
The matrix of claim 1 in which said polyisocyanate is isophorone diisocyanate or methylene bis(cyclohexyl diisocyanate).
Claim 7
Dependent Claim 23 words
The matrix of claim 1 in which up to 100% of the isocyanate groups of the prepolymer are reacted with the modifying compound.
Claim 8
Dependent Claim 34 words
The matrix of claim 1 in which the polyurethane polymer has been activated to convert essentially all of the second functional groups to an active functional group capable of covalently attaching a bioaffinity agent.
Claim 9
Dependent Claim 34 words
The matrix of claim 1 in which the polyurethane polymer has been activated to convert substantially all of the second functional groups to an active functional group capable of covalently attaching a bioaffinity agent.
Claim 10
Dependent Claim 21 words
The matrix of claim 1 in which the support is in the form of a microporous membrane or a particulate media.
Claim 11
Dependent Claim 12 words
The matrix of claim 9 in which the support is silica gel.
Claim 12
Dependent Claim 11 words
The matrix of claim 9 in which the support is charcoal.
Claim 13
Dependent Claim 152 words
The process of preparing an affinity matrix for chromatography or immobilization of biological materials, which matrix is characterized by a biocompatible surface which resists nonspecific protein adsorption, said process comprising the steps of: a) preparing a prepolymer, the units of which are oxyethylene-based alcohols having essentially all of the hydroxyl groups capped with polyisocyanate; b) reacting said polyisocyanate capped prepolymer with a modifying compound having a first functional group which is NCO reactive and a second functional group which is substantially less NCO reactive to form a modified prepolymer; c) coating the modified prepolymer onto a support; d) curing the modified prepolymer with water to form a modified polyurethane polymer characterized by the second functional group inserted in the prepolymer; and e) reacting the modified polyurethane polymer with an activating compound to convert the second functional group of said polymer to an active functional group capable of covalently attaching a bioaffinity agent.
Claim 14
Dependent Claim 152 words
The process of preparing an affinity matrix for chromatography or immobilization of biological materials, which matrix is characterized by a biocompatible surface which resists nonspecific protein adsorption, said process comprising the steps of: a) preparing a prepolymer, the units of which are oxyethylene-based alcohols having essentially all of the hydroxyl groups capped with polyisocyanate; b) reacting said polyisocyanate capped prepolymer with a modifying compound having a first functional group which is NCO reactive and a second functional group which is substantially less NCO reactive to form a modified prepolymer; c) coating the modified prepolymer onto a support; d) curing the modified prepolymer with water to form a modified polyurethane polymer characterized by the second functional group inserted in the prepolymer; and e) reacting the modified polyurethane polymer with an activating compound to convert the second functional group of said polymer to an active functional group capable of covalently attaching a bioaffinity agent.
Claim 15
Dependent Claim 17 words
The process of claim 12 in which a large molar excess of said activating compound is used.
Claim 16
Dependent Claim 35 words
The process of claim 13 in which essentially all of the second functional groups of the modified polyurethane polymer is converted to an active functional group capable of covalently attaching a ligand or binder molecule.
Claim 17
Dependent Claim 35 words
The process of claim 13 in which substantially all of the second functional groups of the modified polyurethane polymer is converted to an active functional group capable of covalently attaching a ligand or binder molecule.
Claim 18
Dependent Claim 21 words
The process of claim 13 in which the modified polyurethane polymer is reacted with the activating compound in a nonaqueous environment.
Claim 19
Dependent Claim 19 words
The process of claim 13 in which the prepolymer is coated onto a support prior to curing with water.
Claim 20
Dependent Claim 23 words
The process of claim 13 in which the prepolymer units are oxyethylene based diols and polyols which are capped with an aliphatic polyisocyanate.
Claim 21
Dependent Claim 19 words
The process of claim 13 in which about 15% to about 30% of the prepolymer isocyanate groups are modified.
Claim 22
Dependent Claim 21 words
The process of claim 13 in which the prepolymer is coated onto a silica or charcoal prior to curing with water.
Claim 23
Dependent Claim 11 words
An affinity chromatographic device comprised of the matrix of claim 1.
Claim 24
Dependent Claim 16 words
An immobilized bioaffinity agent comprising a bioaffinity agent covalently attached to the matrix of claim 1.
Claim 25
Dependent Claim 13 words
An extracorporeal therapeutic device comprised of the immobilized bioaffinity agent of claim 22.
Claim 26
Dependent Claim 36 words
A purification or isolation system for a biologically-active ligand or binder molecule, said system comprising the immobilized bioaffinity agent of claim 22, wherein the bioaffinity agent is capable of selectively binding said ligand or binder molecule.
Claim 27
Dependent Claim 26 words
A diagnostic assay system comprising the affinity matrix of claim 1 having a bioaffinity agent covalently attached thereto, and further comprising a holder for said matrix.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1998-04-03 1998-10-03 1999-04-04 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2002-04-03 2002-10-03 2003-04-04 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2006-04-03 2006-10-03 2007-04-04 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag